Predictive markers in breast cancer - The future

Histopathology

Volumn 52, Issue 1, 2008, Pages 91-98

  Faratian, D ^a   Bartlett, J ^a  

^a Edinburgh Cancer Research Centre   (United Kingdom)

Author keywords

Clinical trial; Predictive biomarkers; PTEN; RTK inhibitors; Topoisomerase II; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; EXEMESTANE; GEFITINIB; GEMCITABINE; HORMONE; IMATINIB; PACLITAXEL; PHOSPHATASE; PROTEIN KINASE B; TAMOXIFEN; TAXANE DERIVATIVE; TOPOISOMERASE II ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG;

BIOSTATISTICS; BREAST CANCER; CLINICAL EVALUATION; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; TISSUE;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 37249078187     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02896.x     Document Type: Review

References (66)

1. Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007 72 7 25.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 235 177 182.
3. Bartlett JMS. Biological predictors of tumour response: natural selection or intelligent design? Advances Breast Cancer 2005 2 11 15.
4. Miller WR, Bartlett JMS, Canney P, Verrill M. Hormonal therapy for postmenopausal breast cancer: the science of sequencing. Breast Cancer Res. Treat. 2007 103 149 160.
5. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 366 2087 2106.
6. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000 406 747 752.
7. Bartlett JMS. Translational research and the development of novel biomarkers in breast cancer. Advan Breast Cancer 2006 3 76 85.
8. Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007 72 7 25.
9. Tovey SM, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JMS. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin. Cancer Res. 2005 11 4835 4842.
10. Johnston SRD, Head J, Pancholi S et al. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin. Cancer Res. 2003 9 524S 532S.
11. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JMS. Expression of the HERI-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 2003 200 290 297.
12. Kirkegaard T, McGlynn LM, Campbell FM et al. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin. Cancer Res. 2007 13 1405 1411.
13. Kirkegaard T, Witton CJ, McGlynn LM et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J. Pathol. 2005 207 139 146.
14. Cannings E, Kirkegaard T, Tovey SM, Dunne B, Cooke TG, Bartlett JMS. Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res. Treat. 2007 102 173 179.
15. Bergqvist J, Elmberger G, Ohd J et al. Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur. J. Cancer 2006 42 1104 1112.
16. Gutierrez MC, Detre S, Johnston S et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 2005 23 2469 2476.
17. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984 226 466 468.
18. Di Leo A, Chan S, Paesmans M et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res. Treat. 2004 86 197 206.
19. Di Leo A, Gancberg D, Larsimont D et al. HER-2 Amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res. 2002 8 1107 1116.
20. Di Leo A, Larsimont D, Gancberg D et al. HER-2 and topo-isomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann. Oncol. 2001 12 1081 1089.
21. Jarvinen TAH, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 2000 156 839 847.
22. Jarvinen TAH, Kononen J, Peltohuikko M, Isola J. Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am. J. Pathol. 1996 148 2073 2082.
23. Knoop AS, Knudsen H, Balslev E et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin and fluorouracil: Danish breast cancer cooperative group. J. Clin. Oncol. 2005 23 7483 7490.
24. Pritchard KI, Shepherd LE, O'Malley FP et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 2006 354 2103 2111.
25. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res. 2001 61 5345 5348.
26. Paik S, Bryant J, Tan-Chiu E et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J. Natl Cancer Inst. 2000 92 1991 1998.
27. Moliterni A, Menard S, Valagussa P et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J. Clin. Oncol. 2003 21 458 462.
28. Poole CJ, Earl HM, Hiller L et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N. Engl. J. Med. 2006 355 1851 1862.
29. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 2003 21 2237 2246.
30. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003 290 2149 2158.
31. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004 350 2129 2139.
32. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. U. S. A. 2004 101 13306 13311.
33. Cappuzzo F, Gregorc V, Rossi E et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J. Clin. Oncol. 2003 21 2658 2663.
34. Parra HS, Cavina R, Latteri F et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br. J. Cancer 2004 91 208 212.
35. Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J. Pathol. 2003 199 411 417.
36. Hirsch FR, Varella-Garcia M, McCoy J et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J. Clin. Oncol. 2005 23 6838 6845.
37. Rampaul RS, Pinder SE, Nicholson RI, Gullick WJ, Robertson JF, Ellis IO. Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv. Anat. Pathol. 2005 12 271 273.
38. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev. 1992 13 3 17.
39. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat. 1994 29 41 49.
40. Tovey SM, Witton CJ, Bartlett JMS, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 2004 6 R246 R251.
41. Rampaul RS, Pinder SE, Wencyk PM et al. Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value? Clin. Cancer Res. 2004 10 2578.
42. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004 10 5367 5374.
43. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006 25 5846 5853.
44. Reis-Filho JS, Pinheiro C, Lambros MB et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J. Pathol. 2006 209 445 453.
45. Kersting C, Kuijper A, Schmidt H et al. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab. Invest. 2006 86 54 61.
46. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum. Pathol. 2007 38 1105 1122.
47. Chan SK, Hill ME, Gullick WJ. The role of the epidermal growth factor receptor in breast cancer. J. Mammary Gland Biol. Neoplasia. 2006 11 3 11.
48. Smith IE, Walsh G, Skene A et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J. Clin. Oncol. 2007 25 3816 3822.
49. Witton CJ, Reeves JR, Going JG, Cooke TG, Bartlett JMS. Coexpression of EGFr, HER2, HER3 and HER4 in primary human breast carcinoma. Breast Cancer Res. Treat. 2001 69 32.
50. Burris HA III., Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 2005 23 5305 5313.
51. Carter TA, Wodicka LM, Shah NP et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl Acad. Sci. U. S. A. 2005 102 11011 11016.
52. Fujita T, Doihara H, Kawasaki K et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br. J. Cancer 2006 94 247 252.
53. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004 6 117 127.
54. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997 275 1943 1947.
55. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002 62 4132 4141.
56. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol. Cancer Res. 2007 5 195 201.
57. Mita MM, Mita A, Rowinsky EK. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer 2003 4 126 137.
58. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 2005 16 525 537.
59. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006 124 471 484.
60. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005 307 1098 1101.
61. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005 8 179 183.
62. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br. J. Cancer 2004 91 1420 1424.
63. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 2001 19 3808 3816.
64. Mauriac L, Keshaviah A, Debled M et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann. Oncol. 2007 18 859 867.
65. Hammond MEH, Taube SE. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin. Oncol. 2002 29 213 221.
66. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res. Treat. 2006 100 229 235.